James Hippel - Jul 12, 2021 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Signature
/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.
Stock symbol
TECH
Transactions as of
Jul 12, 2021
Transactions value $
-$3,500,763
Form type
4
Date filed
7/14/2021, 04:57 PM
Previous filing
Jun 9, 2021
Next filing
Aug 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $1.07M +10K +109.45% $106.59 19.1K Jul 12, 2021 Direct
transaction TECH Common Stock Sale -$271K -600 -3.14% $451.07* 18.5K Jul 12, 2021 Direct F1, F2
transaction TECH Common Stock Sale -$339K -751 -4.05% $451.95* 17.8K Jul 12, 2021 Direct F1, F3
transaction TECH Common Stock Sale -$357K -788 -4.43% $453.21* 17K Jul 12, 2021 Direct F1, F4
transaction TECH Common Stock Sale -$301K -662 -3.89% $454.15* 16.3K Jul 12, 2021 Direct F1, F5
transaction TECH Common Stock Sale -$808K -1.77K -10.85% $455.57* 14.6K Jul 12, 2021 Direct F1, F6
transaction TECH Common Stock Sale -$241K -527 -3.62% $456.41* 14K Jul 12, 2021 Direct F1, F7
transaction TECH Common Stock Sale -$520K -1.14K -8.09% $457.79* 12.9K Jul 12, 2021 Direct F1, F8
transaction TECH Common Stock Sale -$855K -1.86K -14.44% $458.81* 11K Jul 12, 2021 Direct F1, F9
transaction TECH Common Stock Sale -$368K -800 -7.25% $459.64* 10.2K Jul 12, 2021 Direct F1, F10
transaction TECH Common Stock Sale -$276K -600 -5.86% $460.71* 9.64K Jul 12, 2021 Direct F1, F11
transaction TECH Common Stock Sale -$139K -300 -3.11% $462.08* 9.34K Jul 12, 2021 Direct F1, F12
transaction TECH Common Stock Sale -$46.4K -100 -1.07% $463.56* 9.24K Jul 12, 2021 Direct F1
transaction TECH Common Stock Sale -$46.6K -100 -1.08% $466.44* 9.14K Jul 12, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -10K -33.33% $0.00 20K Jul 12, 2021 Common Stock 10K $106.59 Direct F14
holding TECH Stock Options (Right to Buy) 24.5K Jul 12, 2021 Common Stock 24.5K $125.05 Direct F14
holding TECH Stock Options (Right to Buy) 32.6K Jul 12, 2021 Common Stock 32.6K $125.05 Direct F15
holding TECH Restricted Stock Units 3.38K Jul 12, 2021 Common Stock 3.38K Direct F13, F16
holding TECH Stock Options (Right to Buy) 18.1K Jul 12, 2021 Common Stock 18.1K $177.32 Direct F16
holding TECH Stock Options (Right to Buy) 24.1K Jul 12, 2021 Common Stock 24.1K $177.32 Direct F17
holding TECH Restricted Stock Units 3.94K Jul 12, 2021 Common Stock 3.94K Direct F13, F18
holding TECH Stock Options (Right to Buy) 19.9K Jul 12, 2021 Common Stock 19.9K $190.41 Direct F18
holding TECH Stock Options (Right to Buy) 26.6K Jul 12, 2021 Common Stock 26.6K $190.41 Direct F19
holding TECH Restricted Stock Units 3.22K Jul 12, 2021 Common Stock 3.22K Direct F13, F20
holding TECH Stock Options (Right to Buy) 14.4K Jul 12, 2021 Common Stock 14.4K $267.87 Direct F20
holding TECH Stock Options (Right to Buy) 19.1K Jul 12, 2021 Common Stock 19.1K $267.87 Direct F21
holding TECH Stock Options (Right to Buy) 8.33K Jul 12, 2021 Common Stock 8.33K $267.87 Direct F22
holding TECH Stock Options (Right to Buy) 8.33K Jul 12, 2021 Common Stock 8.33K $267.87 Direct F23
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.48 to $451.44, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.59 to $452.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $452.69 to $453.68, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $453.76 to $454.74, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $455.00 to $455.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $456.16 to $456.65, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $457.19 to $458.18, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $458.29 to $459.26, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $459.34 to $460.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $460.39 to $461.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $461.71 to $462.60, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F13 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
F14 Fully exercisable.
F15 Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021.
F16 Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F17 Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
F18 Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F19 Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
F20 Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F21 Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.
F22 Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F23 Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.